Currently out of the existing stock ratings of Drew Ranieri, 71 are a BUY (51.45%), 53 are a HOLD (38.41%), 14 are a SELL (10.14%).

Drew Ranieri

Work Performance Price Targets & Ratings Chart

Analyst Drew Ranieri, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 59.38% that have a potential upside of 15.05% achieved within 101 days.

Drew Ranieri’s has documented 363 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GMED, Globus Medical at 02-Dec-2025.

Wall Street Analyst Drew Ranieri

Analyst best performing recommendations are on NPCE (NEUROPACE).
The best stock recommendation documented was for NPCE (NEUROPACE) at 8/24/2023. The price target of $6 was fulfilled within 1 day with a profit of $0.84 (16.28%) receiving and performance score of 162.79.

Average potential price target upside

of $35.36 (13.37%) on SYK (STRYKER).
of $24.51 (7.99%) on ISRG (INTUITIVE SURGICAL).
of $16.03 (13.95%) on ZBH (ZIMMER BIOMET HOLDINGS).

AGTI Agiliti BVS Bioventus GMED Globus Medical HAE Haemonetics HRC Hill-Rom Holdings ISRG Intuitive Surgical NPCE Neuropace NUVA NuVasive SIBN Si-Bone SYK Stryker TMCI Treace Medical Concepts ZBH Zimmer Biomet Holdings ATEC Alphatec Holdings AVNS Avanos Medical BAX Baxter International IART Integra LifeSciences Holdings NVST Envista Holdings Corp OM Outset Medical TFX Teleflex STVN Stevanato Group SpA ORGO Organogenesis Holdings

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

John Ransom (RAYMOND JAMES)